UNILEVER PLC (UL): what the price assumes

In the published model solve dated 2026-Q2, anchored at $64.43, UNILEVER PLC (UL) is priced for -4.3% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-25.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/UL

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 7.1% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~7.1pp.

Reconcile: at the x-ray's 9.3% required return this reads ~10%/yr; the models below use their own rates.

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

The price is supported by asset-based and relative-multiple value, while earnings-power lands below the price. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Asset, Relative Families that call it expensive: Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.9%); the inversion above states its own rate.

Per-Model Detail (n=18)

Solvency

Bullet Takeaways

• The reported top line went backwards in 2025 while the underlying business grew, because "Underlying sales growth contributed 3.5%, offset by a significant currency impact of (5.9)% and (1.2)% from disposals, net of acquisitions", which is a translation problem rather than a demand problem.
• The company is being taken apart deliberately: the Ice Cream business was demerged in December 2025, and Foods, roughly a quarter of what is left, is now in a pending transaction with McCormick.
• Emerging markets are 59% of turnover, so they carry both the growth and the currency loss, and the next results are scheduled for July 28, 2026.

Bull Case

A screen looking at Unilever in 2025 sees a shrinking company. Turnover fell 3.8% against the prior year. That is the number a filter sorts on, and it is the wrong number. The annual report gives the arithmetic behind it: "Underlying sales growth contributed 3.5%, offset by a significant currency impact of (5.9)% and (1.2)% from disposals, net of acquisitions", with the currency drag "primarily driven by Latin American currencies, the Indian rupee, the US dollar and the Turkish lira, all depreciating against the euro". Volumes did not fall. Prices did not fall. The euro simply got bigger relative to the money the customers pay in. A traditional model fed the reported line sees decline; the business underneath it sold more.

Where that growth comes from matters more than the headline rate. "Emerging markets, which represented 59% of Group turnover, delivered underlying sales growth of 3.5%, led by mid-single-digit growth in Asia Pacific. India grew 4.0% underlying sales". Those are the markets adding households to the branded-goods economy rather than defending share in a static one, and they are the majority of the company. The brand-level detail reads the same way: Dove "delivered double-digit growth driven by the successful launch of its renovated hair care range", core skin care grew mid-single digit led by Vaseline, and skin cleansing grew mid-single digit on price and premium mix. Softness in Sunsilk and Clear came partly from what the filing calls "deliberate tail brand portfolio rationalisation", which is a choice, not a loss.

Capital allocation has been unusually decisive for a company this size. The share count has fallen about 4.3% a year for four years, so a holder who has not bought a share since 2021 owns meaningfully more of the company than they did. Borrowings came down at the same time: the annual report puts total financial liabilities at 28,278 million euros at the end of 2025 against 32,053 million a year earlier. And the portfolio itself is being cut down: the Ice Cream business was demerged on 6 December 2025 into a separately listed company, with the filing recording that the "total gain on the demerger of the Ice Cream business was € 3.4 billion" and a minority stake retained. Buybacks, debt reduction and a demerger inside one year is not the behaviour of a management team waiting to see what happens.

That leaves the question of what the remaining company is worth, and this is where the conventional lenses struggle most. The methods that price a company off five years of averaged profit, capitalized as though nothing ever grows again, are describing a Unilever that no longer exists: it had an ice cream division for four of those five years and is contracted to part with its foods division. Those backward-averaging methods sit further below today's price than any other approach, further even than the forward-projecting ones. What peers fetch lands above the price, and the balance-sheet lenses land within a whisker of it. For a business whose shape is changing on purpose, the second reading is the more honest one.

Bear Case

A consumer staples company trading at a mid-teens multiple of profit is the market telling you it doubts the profit. The doubt here has a specific shape, and it is not about this quarter. Unilever is being dismantled in public. Ice cream is already gone. Foods, about a quarter of revenue, is under agreement to leave. What remains is soap, shampoo, deodorant and household cleaning, sold in categories where price has been the dominant earnings lever, and where the filing records that "Underlying price growth in developed markets was 0.9%". Near-zero pricing means volume has to do the work, and volume is the hardest thing in staples to buy back once it goes.

The currency problem is the second structural issue, and it is not a one-year accident. The growth sits in emerging markets, which the filing puts at "59% of Group turnover", and those are precisely the currencies that fell against the euro: Latin American currencies, the Indian rupee and the Turkish lira among them. A shareholder is paid in reported results, not underlying ones. If the pattern repeats, the company can grow every year in local terms and still hand its owners a smaller number every year, which is exactly what 2025 looked like.

The portfolio risk is more concrete than "execution." Tail brands are being pruned, which shrinks the base before it grows it, and two of the named hair brands were already soft in emerging markets. What a staples and beauty portfolio looks like when the pruning goes wrong is visible next door in this cohort: EL earned an operating margin of 2.9% on $14.8 billion of revenue, having grown revenue 0.3% over the year. That is not a forecast for anyone; it is a demonstration that scale and famous brands do not by themselves protect the earnings line. The comparison that sets the bar is the other one: PG grew revenue 3.3% while earning a 23.2% operating margin on $86.7 billion of revenue.

Which brings the argument back to the price. It is low enough to embed operating profit going into permanent decline, and the bear case is simply that the market may be right. The reported line has already gone backwards once. Net debt of about 25.2 billion dollars does not threaten the company, but it does not shrink when the company does, so a smaller Unilever after the foods transaction carries the same borrowings against a narrower earnings base. Cheap is a fact about the price. Whether it is an opportunity depends entirely on whether the earnings base stops getting smaller.

Valuation

Start with what $60.95 is actually paying for. The market is capitalizing this company at about 15x company-wide operating income, which is low enough that the price sits below what even a 5% a year decline in operating profit would warrant. That is a bound rather than a forecast: there is no growth rate to solve for here, because the price does not require growth at all. It requires the business not to erode faster than that. The calculation behind the bound runs at about a 7.1% cost of capital with 4% growth assumed after a five-year stage.

Against the company's own recent record, that is an undemanding ask. The pace the price embeds sits inside what the business has been delivering, and the overall read is within range rather than stretched, though the comparison set here is thin and the label is better treated as a direction than a verdict.

The methods disagree in a pattern that fits a value situation rather than a growth one. What peers fetch lands above today's price, and the balance-sheet methods land within a rounding error of it. The earnings-power family sits furthest below, and the mechanism is worth naming: that family takes a five-year average of operating profit and capitalizes it assuming no growth whatsoever, so it is describing a company that included an ice cream division for most of the averaging window. Averaging is the wrong instrument for a business being restructured on purpose. The pattern says value support, not a durability premium.

The peer cohort puts the growth question in proportion. Underlying sales growth of 3.5% is not an outlier in this group: CL grew revenue 4.3% and ECL grew 4.9%, while KVUE was flat at a fraction below zero and PG grew 3.3%. The difference is what each is paid for that growth. Unilever's growth arrives inside a portfolio the company is actively cutting, and the market appears to be discounting the transition rather than the categories.

The balance sheet supports rather than settles the case. Borrowings fell over the year, with the annual report putting total financial liabilities at 28,278 million euros at the end of 2025 against 32,053 million a year earlier, and the share count has come down about 4.3% a year over the four years to December 2025. Net debt of roughly 25.2 billion dollars against a market value of 133.1 billion is a manageable load for a business with this cash conversion, and it is not what decides the outcome. What decides it is the size and margin of the company that exists once the foods transaction closes.

Catalysts

The largest identifiable event ahead is the disposal of the foods business. Unilever has been filing communications under Rule 425 through 2026, most recently on July 23, describing "the proposed business combination between McCormick & Company, Inc. and Sandman Corporation, an indirect wholly owned subsidiary of Unilever PLC" and referring to "the pending transaction of Unilever Foods with McCormick". Foods is roughly a quarter of the revenue base, so completion would leave a materially different company: three related personal and home care groups rather than four business groups spanning food and non-food.

That follows a separation already completed. On 6 December 2025 the ice cream business was demerged into a separately listed company, quoted in Amsterdam, London and New York, with the annual report recording that the "total gain on the demerger of the Ice Cream business was € 3.4 billion" and a minority holding retained. Two structural changes inside roughly a year mean the year-over-year comparisons that arrive next will be difficult to read at the headline level, and the underlying rate will carry the information.

The next scheduled print is on July 28, 2026. Two lines in it are worth more than the headline: whether underlying sales growth holds near the 3.5% pace the annual report recorded, and how much of it survives translation this time. Developed-market pricing was running at 0.9%, so any improvement in the reported figure has to come from volume or from currencies stopping their slide, and only one of those is inside management's control.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

• PG (PROCTER & GAMBLE CO)
• FY2025 10-K: …innovation) was offset by declines in Greater China and Asia Pacific (both due to market contraction). Organic sales increased low single digits driven by low single-digit increases in North America and Europe, partially offset by a high single-digit decline in IMEA. Global market share of the fabric care category…
• FY2025 10-K: …increase, partially offset by unfavorable foreign exchange. The unit volume increase was due to increases in North America (due to share growth) and Latin America (due to market growth). Organic sales increased mid-single digits due to double-digit growth in Latin America, mid-single-digit growth in Europe and low…
• CL (COLGATE-PALMOLIVE COMPANY)
• FY2025 10-K: 2024 was primarily due to decreases in Oral Care and Personal Care organic sales. The decrease in Oral Care was primarily due to an organic sales decline in the toothpaste category, partially offset by organic sales growth in the manual toothbrush category. The decrease in Personal Care was primarily due to an organic…
• FY2025 10-K: …omni-channel demand generation; leading in capabilities such as data, analytics and AI; and evolving our high-impact, inclusive culture are the keys to accelerating growth going forward. Our commitment to these priorities, the strength of our brands, our resilient global supply chain, the breadth of our global…
• KVUE (Kenvue Inc.)
• FY2025 10-K: …2) global CPG companies that operate in similar or adjacent categories, 3) regional companies that operate in our categories within the markets in which we compete, 4) generic OTC manufacturers and retailers', including our customers', private-label brands in both traditional retail and online, and 5) emerging…
• FY2025 10-K: Care (Digestive Health, Smoking Cessation, Eye Care, and Other) Skin Health and Beauty Face and Body Care Hair, Sun, and Other Essential Health Oral Care Baby Care Other Essential Health (Women's Health, Wound Care, and Other) The Company's product categories as a percentage of Net sales for the fiscal twelve months…
• HLN (Haleon plc)
• FY2025 20-F: …adjusting items, which are defined under Use of non-IFRS Measures on page 205. A reconciliation between operating profit and adjusted operating profit is included under Use of non-IFRS Measures. 3. On a segment basis, adjusted operating profit is the measure of segment profit or loss reviewed by the Company's chief…
• FY2025 20-F: …progress in reducing SKUs, packaging specifications and formulations. This, combined with pricing resulted in adjusted gross profit growth of 4.4% (constant currency) and 220bps of margin expansion (constant currency) (reported: 3.8% with 350bps of margin expansion). Unlocking efficiencies across the supply chain…
• EL (Estee Lauder Companies Inc)
• FY2025 10-K: …subsidies in China. 41 Table of Contents OPERATING RESULTS Year Ended June 30, ($ in millions) 2025 2024 As Reported: Operating (loss) income $ (785) $ 970 $ Change from prior year (1,755) (539) % Change from prior year (100+)% (36) % Operating Margin (5.5) % 6.2 % Non-GAAP Financial Measure (1) : % Change in…
• FY2025 10-K: Product Categories and Geographic Regions exclude the fiscal 2025 and fiscal 2024 impacts of returns/(return adjustments) associated with restructuring and other activities of approximately $(3) million and $1 million, respectively. Product Categories Reported net sales for our product categories for the years ended…
• ECL (ECOLAB INC.)
• FY2025 10-K: …in basic industries. Global high-tech reported strong double-digit sales growth driven by data centers and microelectronics. Downstream reported sales growth in North America was partially offset by softer sales in other international regions. Manufacturing reported solid growth driven by food & beverage. Basic…
• FY2025 10-K: …in the above table do not necessarily sum due to rounding. ​ Net Sales ​ Fixed currency sales were stable in 2025. Organic sales for Global Institutional & Specialty increased 3% in 2025 with growth in both operating segments. Organic sales increased in 2024 driven by outperformance of end-market trends. At an…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.